Innovative Drug Delivery Solution Showcased on Global Stage
At one of the pharmaceutical industry’s most influential gatherings, BIO USA, Huonslab—an R&D subsidiary of Huons Group—presented its breakthrough in drug formulation technology. The South Korea-based company introduced its proprietary HyDIFFUZE™ platform, a cutting-edge method that enables the transformation of intravenous (IV) antibody therapeutics into subcutaneous (SC) injections.
This platform is built around human hyaluronidase, an enzyme that breaks down hyaluronic acid under the skin to help drugs spread more efficiently. This approach not only makes administration less invasive for patients but also offers pharmaceutical companies a pathway to simplify treatment protocols.
The transition from IV to SC delivery has the potential to significantly reduce treatment time, improve patient comfort, and lower hospital costs. By positioning itself at the forefront of this shift, Huonslab has caught the attention of key players in the global pharmaceutical sector.
HLB3-002: A Promising Standalone Solution
Central to Huonslab’s presentation was HLB3-002, a biologic drug developed using the HyDIFFUZE™ process. This product stands out for its high purity and yield, achieved without producing fragmented byproducts—an important advancement in formulation science. HLB3-002 shares the same amino acid sequence as naturally occurring human hyaluronidase, offering strong safety credentials and clinical compatibility.
In recent in vivo studies, HLB3-002 demonstrated similar pharmacokinetics and drug dispersion performance when compared to existing SC formulations. These results point to its viability as a standalone alternative to Hylenex, a widely used hyaluronidase-based product.
The drug is currently undergoing a pivotal Phase 1 clinical trial in Korea, where all patient enrollments have already been completed. Depending on the final outcomes, the company plans to submit a biological license application to the national regulatory body later this year.
Huonslab’s approach not only reflects scientific rigor but also strong commercial foresight. A successful rollout of HLB3-002 would open doors to strategic collaborations and licensing agreements, particularly in markets looking for more efficient and cost-effective drug delivery options.
Global Interest and Expanding Applications
The unveiling of HyDIFFUZE™ and HLB3-002 has sparked considerable international interest, not just for therapeutic use, but across a broader range of medical fields. The subcutaneous delivery method is gaining traction in plastic surgery, beauty and aesthetics, and in pain and swelling management—areas where precise, fast-acting injections are essential.
Huonslab’s platform addresses the growing demand for convenience and efficiency in medical treatments. With its compatibility across various drug classes, HyDIFFUZE™ offers pharmaceutical companies a versatile tool to modernize their pipelines and extend the lifecycle of existing products through new SC formulations.
The technology is also being seen as a potential technology transfer opportunity, opening the door for partnerships with overseas biotech and pharma firms seeking to enhance their formulation capabilities.
R&D Beyond Drug Delivery
While HyDIFFUZE™ is currently the centerpiece of Huonslab’s innovation strategy, the company is also pushing the boundaries in early-stage drug development. In parallel with the HLB3-002 program, Huonslab is advancing a preclinical pipeline that targets critical global health issues including Alzheimer’s disease, obesity, and diabetes.
By balancing innovation in drug delivery with novel therapeutic development, Huonslab is carving out a unique space in the biotech landscape. Its work not only serves the needs of the parent Huons Group but also contributes to a broader vision of future-ready healthcare solutions.
The successful showcase at BIO USA has underscored the company’s readiness to move from laboratory breakthroughs to commercial reality—positioning itself as a high-potential partner for future pharmaceutical innovation.